Report Title:

Stem Cell Research; UH Medical School

Description:

Sets state policy for stem cell research. Requires UH to develop plan to establish an institute for regenerative medicine at school of medicine no later than 12/31/2006.

HOUSE OF REPRESENTATIVES

H.B. NO.

1648

TWENTY-THIRD LEGISLATURE, 2005

 

STATE OF HAWAII

 


 

A BILL FOR AN ACT

 

relating to stem cell research.

 

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

PART I

SECTION 1. The legislature finds that an estimated 128,000,000 Americans suffer from the crippling economic and psychological burden of chronic, degenerative, and acute diseases, including diabetes, Parkinson's disease, cancer, and Alzheimer's disease. The costs of treatment and lost productivity of chronic, degenerative, and acute diseases in the United States run into hundreds of billions of dollars every year. Yet, the estimates of these economic costs do not account for the extreme cost in human loss and suffering associated with these conditions.

On the other hand, stem cell research could lead to unprecedented treatments and potential cures for diabetes, Alzheimer's disease, cancer, and other diseases. Stem cell research offers immense promise for developing new medical therapies for these debilitating diseases.

The United States has historically been a haven for open scientific inquiry and technological innovation; and this environment, combined with the commitment of public and private resources, has made the United States the preeminent world leader in biomedicine and biotechnology. The biomedical industry is a critical and growing component of Hawaii's economy, and its development would be significantly hampered by any limitation imposed on stem cell research.

Open scientific inquiry and research endeavors supported by public funding will be essential to realizing the promise of stem cell research. Publicly funded stem cell research, conducted under established standards of open scientific exchange, peer review, and public oversight, offers the most efficient and responsible means of fulfilling the promise of the use of stem cells in providing regenerative medical therapies.

The legislature further finds that stem cell research, including the use of embryonic stem cells for medical research, raises significant ethical and policy concerns. Public policy on stem cell research must balance ethical and medical considerations. While not unique, these ethical and policy concerns associated with stem cell research must be well thought out. The policy of this State must be based on an understanding of the science associated with stem cell research and grounded on a thorough consideration of the ethical concerns regarding this research. Public policy on stem cell research must be crafted to ensure that researchers have the research and ethical tools necessary to fulfill the promise of stem cell research.

SECTION 2. Chapter 321, Hawaii Revised Statutes, is amended by adding a new part to be appropriately designated and to read as follows:

"Part   .  STEM CELL RESEARCH; POLICY

§321- Stem cell research; policy. (a) The policy of the State relating to stem cell research shall be as follows:

(1) Research involving the derivation and use of human embryonic stem cells, human embryonic germ cells, and human adult stem cells from any source, including somatic cell nuclear transplantation, shall be:

(A) Permitted in this State;

(B) Conducted with full consideration of the ethical and medical implications of this research; and

(C) Reviewed by an approved institutional review board;

(2) A physician, or other health care provider, delivering fertility treatment shall provide the patient with timely, relevant, and appropriate information to allow the patient to make an informed and voluntary choice regarding the disposition of any human embryos remaining following the fertility treatment;

(3) Any individual to whom information is provided pursuant to paragraph (2) shall be presented with the option of storing unused embryos, donating them to another individual, discarding the embryos, or donating the remaining embryos for research;

(4) Any individual who elects to donate embryos remaining after fertility treatments for research shall provide written consent; and

(5) A person may not knowingly, for valuable consideration, purchase or sell embryonic or cadaveric fetal tissue for research purposes pursuant to this chapter.

(b) For purposes of this section, "valuable consideration" does not include reasonable payment for the removal, processing, disposal, preservation, quality control, storage, transplantation, or implantation of embryonic or cadaveric fetal tissue.

(c) Embryonic or cadaveric fetal tissue may be donated for research purposes pursuant to this part.

(d) The director of health shall adopt rules in accordance with chapter 91 to implement this part."

PART II

SECTION 3. The legislature finds that the reestablishment of the University of Hawaii's school of medicine in the Kakaako area is generating an enormous stimulus towards medical and scientific innovation and presents a tremendous opportunity for the State to improve its position in the leading edge field of biotechnology and stem cell research. In conjunction with the state policy on stem cell research, an institute for regenerative medicine located at the University of Hawaii school of medicine could become a world leader in innovative stem cell research. Not only will humanity benefit, but this type of medical research will also significantly reduce state health care costs in the future. The State will benefit from royalties, patents, and licensing fees arising from discoveries and innovations relating to stem cell research. This research will create significant numbers of high-end jobs and generate millions of dollars as it expands the State's tax base.

The purpose of this part is to lay the foundation for the establishment of an institute for regenerative medicine at the University of Hawaii's school of medicine.

SECTION 4. (a) The president shall develop and the board of regents of the University of Hawaii shall approve for submission to the legislature a plan to establish an institute for regenerative medicine at the school of medicine. The institute for regenerative medicine shall have the following purposes:

(1) Support stem cell research and other vital research opportunities to realize therapies, protocols, and medical procedures that will result in, as speedily as possible, the cure for or substantial mitigation of major diseases, injuries, and orphan diseases;

(2) Support all stages of the process of developing cures, from laboratory research through successful clinical trials; and

(3) Establish the appropriate regulatory standards and oversight bodies for research and facilities development.

(b) The plan to be developed by the president and approved by the board of regents of the University of Hawaii concerning the establishment of the institute for regenerative medicine shall ensure that:

(1) Use of research funds made available to the institute will be maximized by giving priority to stem cell research that has the greatest potential for therapies and cures, specifically focused on pluripotent stem cell and progenitor cell research among other vital research opportunities that cannot, or are unlikely to, receive timely or sufficient federal funding, unencumbered by limitations that would impede the research; provided that research shall be subject to accepted patient disclosure and patient consent standards;

(2) Research is conducted safely and ethically by including provisions to require compliance with standards based on national models that protect patient safety, patient rights, and patient privacy;

(3) Use of any funds made available to the institute is prohibited for human reproductive cloning;

(4) The Hawaii health care system is improved and the long-term health care cost burden on Hawaii is reduced through the development of therapies that treat diseases and injuries with the ultimate goal to cure them; and

(5) Strict fiscal and public accountability is implemented through mandatory independent audits, open meetings, public hearings, and annual reports to the public.

(c) The institute for regenerative medicine shall have the right to conduct stem cell research, which includes research involving adult stem cells, cord blood stem cells, pluripotent stem cells, and progenitor cells. For the purposes of this section, "pluripotent stem cells" are cells that are capable of self-renewal and have broad potential to differentiate into multiple adult cell types. Pluripotent stem cells may be derived from somatic cell nuclear transfer or from surplus products of in vitro fertilization treatments, when such products are donated under appropriate informed consent procedures. "Progenitor cells" are multipotent or precursor cells that are partially differentiated, but retain the ability to divide and give rise to differentiated cells.

(d) No funds authorized for, or made available to, the institute for regenerative medicine shall be used for research involving human reproductive cloning.

(e) The University of Hawaii may issue general obligation bonds to fund the development and construction of the institute for regenerative medicine.

(f) The president shall develop and the board of regents shall approve the plan to establish the institute for regenerative medicine no later than November 30, 2006, and submit the finalized plan to the legislature no later than December 31, 2006, together with any necessary proposed legislation, such as funding needs, for introduction in the regular session of 2007.

PART III

SECTION 5. This Act shall take effect upon its approval.

INTRODUCED BY:

_____________________________